Stifel Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $41

Benzinga · 10/14 13:25
Stifel analyst Bradley Canino maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $40 to $41.